DICE Therapeutics, Inc. - DICE STOCK NEWS

DICE Therapeutics reported positive Phase 1 data for its oral IL-17 antagonist, DC-806, showing a mean percentage reduction in psoriasis severity of 43.7% compared to 13.3% for placebo. The company completed a $345 million public offering, enhancing its financial capacity to fund operations through 2026. DICE aims to submit an IND application for DC-806 in early 2023 and plans to initiate a Phase 2b trial. R&D expenses rose to $14.7 million, while net loss increased to $20.6 million for Q3 2022.

DICE Therapeutics (Nasdaq: DICE), a biopharmaceutical firm focused on developing novel oral therapeutics for chronic diseases, has announced its participation in key investor conferences. Management will present at the Guggenheim 4th Annual Immunology and Neurology Day on November 15, 2022, and the Stifel 2022 Healthcare Conference on November 16, 2022. Additionally, a fireside chat is scheduled for the Evercore ISI 5th Annual HealthCONx Conference on November 30, 2022. Presentations will be available for 90 days post-event on the company's website.

DICE Therapeutics, Inc. (Nasdaq: DICE) successfully closed an upsized public offering of 9,452,054 common shares on October 17, 2022, raising approximately $345 million at a price of $36.50 per share. The offering included the full exercise of underwriters’ option for 1,232,876 additional shares. BofA Securities, SVB Securities, Evercore ISI, and Guggenheim Securities managed the offering. The shares were offered under a previously filed SEC registration statement, with relevant prospectus details available on the SEC’s website.

DICE Therapeutics, Inc. (Nasdaq: DICE) announced an upsized public offering of 8,219,178 shares of its common stock at $36.50 each, projected to raise approximately $300 million before expenses. The underwriters have a 30-day option to purchase an additional 1,232,876 shares. The offering is set to close around October 17, 2022, pending customary conditions. DICE focuses on developing novel oral therapeutics targeting chronic immunological diseases, leveraging its DELSCAPE platform.

DICE Therapeutics has announced a public offering of $250 million shares of its common stock, with an option for underwriters to purchase an additional $37.5 million. The offering is subject to market conditions and other factors, with no guarantee of completion or terms. BofA Securities, SVB Securities, Evercore ISI, and Guggenheim Securities are the joint book-running managers for this offering. The shares will be offered under a registration statement previously filed with the SEC, and a prospectus supplement will be available.

DICE Therapeutics (DICE) announced significant progress from its Phase 1 clinical trial of DC-806, an oral small molecule targeting IL-17, showing a noteworthy 43.7% reduction in PASI for psoriasis patients at a high dose, versus 13.3% for placebo, with an exploratory p-value of 0.0008. The drug demonstrated excellent tolerability, devoid of serious adverse events, and maintained a favorable pharmacokinetic profile. As a result, DICE plans to advance DC-806 into a Phase 2b trial in 2023, solidifying its position as a potential best-in-class therapy for psoriasis.

DICE Therapeutics (DICE) announced completion of enrollment in a Phase 1 clinical trial for its lead oral IL-17 antagonist, DC-806, aimed at treating psoriasis. Topline proof-of-concept data are expected in the second half of 2022. Financially, DICE reported cash reserves of $282.2 million as of June 30, 2022, sufficient to fund operations through mid-2024. However, R&D expenses surged to $14.3 million, reflecting a significant increase in personnel and development costs. The net loss for Q2 2022 was $21.5 million, compared to $7.4 million in Q2 2021.

DICE Therapeutics has completed enrollment for its Phase 1 clinical trial of DC-806, an oral antagonist targeting IL-17, pivotal in treating psoriasis and other autoimmune diseases. This first-in-human study will assess safety and provide proof-of-concept data in both healthy volunteers and psoriasis patients. Topline data is anticipated in 2H 2022. The company aims to create effective oral medications that can match the benefits of existing injectable biologics, addressing a significant market need as over 8 million Americans are affected by psoriasis.

DICE Therapeutics, a biopharmaceutical company focused on immunology, will present at the Jefferies Healthcare Conference on June 9, 2022, at 2:30 p.m. ET. This presentation will highlight their innovative approach using proprietary technology to develop oral therapeutics for chronic diseases. Key therapeutic targets include IL-17, α4ß7 integrin, and αVß1/αVß6 integrin. A live and archived webcast of the presentation can be found on their website, available for 90 days post-event.